Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window. Local targets link to admitted publications; unresolved targets remain external evidence.
Epidermal growth factor receptor targeting in cancer: a review of trends and strategies
10.1016/j.biomaterials.2013.07.100 · 2013 · External reference
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII)
2015 · External reference
Epidermal EGFR controls cutaneous host defense and prevents inflammation
10.1126/scitranslmed.3005886 · 2013 · External reference
Genetic ablation of epidermal EGFR reveals the dynamic origin of adverse effects of anti-EGFR therapy
10.1126/scitranslmed.3005773 · 2013 · External reference
A Phase II study of cetuximab (Erbitux) plus FOLFIRI for irinotecan and oxaliplatin-refractory metastatic colorectal cancer
10.3346/jkms.2007.22.s.s98 · 2007 · External reference
FDA review of a panitumumab (Vectibix) clinical trial for first-line treatment of metastatic colorectal cancer
10.1634/theoncologist.2008-0254 · 2009 · External reference
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management
10.1634/theoncologist.12-5-610 · 2007 · External reference
Mucins in cancer: function, prognosis and therapy
10.1038/nrc2761 · 2009 · External reference
MUC1: a multifaceted oncoprotein with a key role in cancer progression
10.1016/j.molmed.2014.02.007 · 2014 · External reference
Mucin-1: a promising pan-cancer therapeutic target
10.1038/s41698-025-01016-2 · 2025 · External reference
Tumor necrosis factor-alpha converting enzyme/ADAM 17 mediates MUC1 shedding
10.1074/jbc.m208326200 · 2003 · External reference
Potential of anti-MUC1 antibodies as a targeted therapy for gastrointestinal cancers
10.3390/vaccines8040659 · 2020 · External reference
Targeting the human MUC1-C oncoprotein with an antibody-drug conjugate
10.1172/jci.insight.99880 · 2018 · External reference
Transgenic MUC1 interacts with epidermal growth factor receptor and correlates with mitogen-activated protein kinase activation in the mouse mammary gland
10.1074/jbc.m011248200 · 2001 · External reference
MUC1 stimulates EGFR expression and function in endometrial cancer
10.18632/oncotarget.8743 · 2016 · External reference
Interaction of galectin-3 with MUC1 on cell surface promotes EGFR dimerization and activation in human epithelial cancer cells
10.1038/cdd.2017.119 · 2017 · External reference
Muc1-c is a common driver of acquired osimertinib resistance in NSCLC
10.1016/j.jtho.2023.10.017 · 2024 · External reference
EGFR and MUC1 as dual-TAA drug targets for lung cancer and colorectal cancer
10.3389/fonc.2024.1433033 · 2024 · External reference
Enzymatic glycan remodeling-metal free click (GlycoConnectTM) provides homogenous antibody-drug conjugates with improved stability and therapeutic index without sequence engineering
10.1080/19420862.2022.2078466 · 2022 · External reference
Advancing bispecific antibody discovery using common light chain immunoglobulin humanized mouse
10.1158/1538-7445.am2021-1861 · 2021 · External reference
“Knobs-into-holes” engineering of antibody CH3 domains for heavy chain heterodimerization
10.1093/protein/9.7.617 · 1996 · External reference
Anti-EGFR therapies in nasopharyngeal carcinoma
10.1016/j.biopha.2020.110649 · 2020 · External reference
Clinical efficacy and toxicity of anti-EGFR therapy in common cancers
10.1155/2009/567486 · 2009 · External reference
Mechanism of lethal skin toxicities induced by epidermal growth factor receptor inhibitors and related treatment strategies
10.3389/fonc.2022.804212 · 2022 · External reference
Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study
10.1200/jco-24-01544 · 2025 · External reference
Evaluation of safety of treatment with anti-epidermal growth factor receptor antibody drug conjugate MRG003 in patients with advanced solid tumors: a phase 1 nonrandomized clinical trial
10.1001/jamaoncol.2022.0503 · 2022 · External reference
Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance
10.1016/j.addr.2008.04.012 · 2008 · External reference
The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial results
10.1038/s41467-023-44533-z · 2024 · External reference
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
10.1016/s1470-2045(17)30604-6 · 2017 · External reference
BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
10.1016/s1470-2045(24)00159-1 · 2024 · External reference
Antibody coadministration as a strategy to overcome binding-site barrier for ADCs: a quantitative investigation
10.1208/s12248-019-0387-x · 2020 · External reference
